Superbugs & superdrugs - Overcoming resistance

Crowne Plaza Hotel - St James, London, United Kingdom (March 17-18, 2010)

SMi's 12th Annual Conference will bring you up to date with new and emerging products in the antimicrobials market, with a particular focus on antibacterials and antifungals and allow you to learn from and network with some of the leading individuals and organizations in this ever important area.

Since their discovery antimicrobial drugs have dramatically reduced the danger of infectious diseases. However the emergence of resistant strains of microbes has now greatly reduced the effectiveness of these drugs. Resistant strains are responsible for regular headline news, from E. coli outbreaks to the H1N1 pandemic and cost global health services ever increasing amounts of money.

The recent ECDC/EMEA Technical Report - The bacterial challenge: time to react has highlighted the urgent need for development of new antimicrobial drugs.

"Industry's pipeline contains very few new antibiotics active against multidrug-resistant bacteria. Without stimulating research and development into new antibiotics, an increasing number of infected patients will be without effective treatment". Bo Aronsson, EMEA.

"A future without effective antibiotics will exacerbate a situation where already at least 25,000 patients in the EU each year die from infections due to multidrug-resistant bacteria. Patients suffering from healthcare-associated infections will be particularly hard hit" Dominique Monnet, ECDC

Více: http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3198